Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Howard Williams who wrote (11181)	4/24/2012 4:34:53 PM
From: NTTG	3 Recommendations Read Replies (1) \| Respond to of 13111

FDA met with the company for two post PII meeting, then declined the third requested meeting some time ago,, told PVCT they had all the information they needed. The SPA process we were talking about today was addressing the process after the first 45 day review response, right? "While the review process could occur in as little as 45 days from the date of submission, we expect it will be an iterative process, and thus, more time may be required to work with the FDA on a study design agreement." That is the repetitive processes yet to come, Dees was clear about that. It appears PVCT wanted something out of the third meeting but did not get the chance...now they have to write, but are also preparing investors for the real possibility that they will miss the mark with a SPA Who is trying to cloud the issue here Howard?